Provided by Tiger Trade Technology Pte. Ltd.

Outlook Therapeutics, Inc.

2.05
-0.0100-0.49%
Post-market: 2.04-0.0100-0.49%19:53 EST
Volume:2.05M
Turnover:4.12M
Market Cap:91.06M
PE:-1.37
High:2.09
Open:2.08
Low:1.95
Close:2.06
52wk High:3.39
52wk Low:0.7900
Shares:44.42M
Float Shares:24.35M
Volume Ratio:0.87
T/O Rate:8.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5016
EPS(LYR):-4.0632
ROE:-3.65%
ROA:-130.65%
PB:-2.45
PE(LYR):-0.50

Loading ...

H.C. Wainwright Sticks to Its Hold Rating for Outlook Therapeutics (OTLK)

TIPRANKS
·
Nov 15

Outlook Therapeutics announces acceptance of BLA for ONS-5010

TIPRANKS
·
Nov 13

Outlook Therapeutics Inc - FDA Sets Pdufa Goal Date of December 31, 2025

THOMSON REUTERS
·
Nov 13

Outlook Therapeutics Inc: Ons-5010, IF Approved, Will Be Branded as Lytenava for Treatment of Wet Amd

THOMSON REUTERS
·
Nov 13

Outlook Therapeutics Inc - IF Approved, Ons-5010 to Be Branded as Lytenava for Wet Amd

THOMSON REUTERS
·
Nov 03

Outlook Therapeutics Plans to Resubmit ONS-5010 Biologics License Application Before Year-End

MT Newswires Live
·
Sep 30

BRIEF-Outlook Therapeutics Provides Update On Type A Meeting With FDA

Reuters
·
Sep 29

Outlook Therapeutics Provides Update on Type a Meeting With FDA

THOMSON REUTERS
·
Sep 29

Outlook Therapeutics Inc - to Resubmit Bla by End of 2025

THOMSON REUTERS
·
Sep 29

U.S. RESEARCH ROUNDUP-Apple, GE Aerospace, Tesla

Reuters
·
Sep 22

Outlook Therapeutics Inc : Ascendiant Capital Markets Cuts Target Price to $8 From $21

THOMSON REUTERS
·
Sep 22

Outlook Therapeutics Announces Departure of Chief Commercial Officer Jeff Evanson

Reuters
·
Sep 06

BRIEF-Outlook Therapeutics Requests Type A Meeting With FDA

Reuters
·
Sep 03

Outlook Therapeutics Requests Type a Meeting With FDA

THOMSON REUTERS
·
Sep 02

Outlook Therapeutics Shares Fall After HC Wainwright Downgrade

MT Newswires Live
·
Aug 30

BUZZ-U.S. STOCKS ON THE MOVE-Caterpillar, Dell, Dollar Tree

Reuters
·
Aug 29

HC Wainwright Downgrades Outlook Therapeutics to Neutral From Buy, Adjusts Price Target to $1 From $3

MT Newswires Live
·
Aug 29

BUZZ-Outlook falls as Wainwright downgrades stock after US FDA declines to approve eye drug

Reuters
·
Aug 29

Outlook Therapeutics Inc : H.c. Wainwright Cuts to Neutral From Buy

THOMSON REUTERS
·
Aug 29

Outlook Therapeutics Is Maintained at Neutral by Chardan Capital

Dow Jones
·
Aug 29